tbuckley/cabot-search huggingface dataset:
Targeting Chemotherapy to Decondensed H3K27me3-Marked Chromatin of AML Cells Enhances Leukemia Suppression
Authors: Patrizia Porazzi, Svetlana Petruk, Luca Pagliaroli, Marco De Dominici, David Deming, Matthew V. Puccetti, Saul Kushinsky, Gaurav Kumar, Valentina Minieri, Elisa Barbieri, Sandra Deliard, Alexis Grande, Marco Trizzino, Alessandro Gardini, Eli Canaani, Neil Palmisiano, Pierluigi Porcu, Adam Ertel, Paolo Fortina, Christine M. Eischen, Alexander Mazo, Bruno Calabretta
Journal: Cancer Research (2021)

Despite treatment with intensive chemotherapy, acute myelogenous leukemia (AML) remains an aggressive malignancy with a dismal outcome in most patients. We found that AML cells exhibit an unusually rapid accumulation of the repressive histone mark H3K27me3 on nascent DNA. In cell lines, primary cells and xenograft mouse models, inhibition of the H3K27 histone methyltransferase EZH2 to decondense the H3K27me3-marked chromatin of AML cells enhanced chromatin accessibility and chemotherapy-induced DNA damage, apoptosis, and leukemia suppression. These effects were further promoted when chromatin decondensation of AML cells was induced upon S-phase entry after release from a transient G1 arrest mediated by CDK4/6 inhibition. In the p53-null KG-1 and THP-1 AML cell lines, EZH2 inhibitor and doxorubicin cotreatment induced transcriptional reprogramming that was, in part, dependent on derepression of H3K27me3-marked gene promoters and led to increased expression of cell death-promoting and growth-inhibitory genes.In conclusion, decondensing H3K27me3-marked chromatin by EZH2 inhibition represents a promising approach to improve the efficacy of DNA-damaging cytotoxic agents in patients with AML. This strategy might allow for a lowering of chemotherapy doses, with a consequent reduction of treatment-related side effects in elderly patients with AML or those with significant comorbidities. SIGNIFICANCE: Pharmacological inhibition of EZH2 renders DNA of AML cells more accessible to cytotoxic agents, facilitating leukemia suppression with reduced doses of chemotherapy.See related commentary by Adema and Colla, p. 359.
Treating Insomnia with High Risk of Depression Using Therapist-Guided Digital Cognitive, Behavioral, and Circadian Rhythm Support Interventions to Prevent Worsening of Depressive Symptoms: A Randomized Controlled Trial
Authors: Jeanne Leerssen, Oti Lakbila-Kamal, Laura M.S. Dekkers, Savannah L.C. Ikelaar, Anne C.W. Albers, Tessa F. Blanken, Jaap Lancee, Glenn J.M. van der Lande, Teodora Maksimovic, Sophie E. Mastenbroek, Joyce E. Reesen, Sjors van de Ven, Tanja van der Zweerde, Jessica C. Foster-Dingley, Eus J.W. Van Someren
Journal: Psychotherapy and Psychosomatics (2021)

&lt;b&gt;&lt;i&gt;Introduction:&lt;/i&gt;&lt;/b&gt; The global disease burden of major depressive disorder urgently requires prevention in high-risk individuals, such as recently discovered insomnia subtypes. Previous studies targeting insomnia with fully automated eHealth interventions to prevent depression are inconclusive: dropout was high and likely biased, and depressive symptoms in untreated participants on average improved rather than worsened. &lt;b&gt;&lt;i&gt;Objective:&lt;/i&gt;&lt;/b&gt; This randomized controlled trial aimed to efficiently prevent the worsening of depressive symptoms by selecting insomnia subtypes at high risk of depression for internet-based circadian rhythm support (CRS), cognitive behavioral therapy for insomnia (CBT-I), or their combination (CBT-I+CRS), with online therapist guidance to promote adherence. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; Participants with an insomnia disorder subtype conveying an increased risk of depression (&lt;i&gt;n&lt;/i&gt; = 132) were randomized to no treatment (NT), CRS, CBT-I, or CBT-I+CRS. The Inventory of Depressive Symptomatology – Self Report (IDS-SR) was self-administered at baseline and at four follow-ups spanning 1 year. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; Without treatment, depressive symptoms indeed worsened (&lt;i&gt;d&lt;/i&gt; = 0.28, &lt;i&gt;p&lt;/i&gt; = 0.041) in high-risk insomnia, but not in a reference group with low-risk insomnia. Therapist-guided CBT-I and CBT-I+CRS reduced IDS-SR ratings across all follow-up assessments (respectively, &lt;i&gt;d&lt;/i&gt; = –0.80, &lt;i&gt;p&lt;/i&gt; = 0.001; &lt;i&gt;d&lt;/i&gt; = –0.95, &lt;i&gt;p&lt;/i&gt; &amp;#x3c; 0.001). Only CBT-I+CRS reduced the 1-year incidence of clinically meaningful worsening (&lt;i&gt;p&lt;/i&gt; = 0.002). Dropout during therapist-guided interventions was very low (8%) compared to previous automated interventions (57–62%). &lt;b&gt;&lt;i&gt;Conclusions:&lt;/i&gt;&lt;/b&gt; The findings tentatively suggest that the efficiency of population-wide preventive strategies could benefit from the possibility to select insomnia subtypes at high risk of developing depression for therapist-guided digital CBT-I+CRS. This treatment may provide effective long-term prevention of worsening of depressive symptoms. &lt;b&gt;&lt;i&gt;Trial registration:&lt;/i&gt;&lt;/b&gt; the Netherlands Trial Register (NL7359).
Abstract 16803: Cabozantinib Induced Cardiomyopathy; Second Reported Case Of A Rare Adverse Effect
Authors: Mian Tanveer Ud Din, Palash Asawa, Namita Joseph, Anita Radhakrishnan
Journal: Circulation (2021)

Case Presentation: A 27-year-old female with no prior medical history was diagnosed with metastatic paraganglioma in 2016. She was started on Cyclophosphamide, Vincristine and Dacarbazine and eventually transitioned to Pembrolizumab for 2 years. Due to progression of disease, she was started on compassionate 40 mg daily Cabozantinib in 2019. Echocardiogram at that time revealed normal ventricular function. One month later, she presented with new onset hypoxic respiratory failure. ProBNP was elevated to 7854 pg/nl. TTE showed moderate pericardial effusion with cardiac tamponade physiology and LVEF of 30%. Cabozantinib was discontinued due to elevated LFT. Repeat TTE after 1 month showed recovery of LVEF to 55% and only trace pericardial effusion. Due to her aggressive malignancy Cabozantinib was reinitiated at 20mg daily. Her LVEF remained stable on multiple serial TTE for 1 year so an attempt at Cabozantinib 40 mg was made once again. One month later, she had worsening dyspnea and TTE showed LVEF drop to 35%. Cardiac MRI revealed LVEF 37% with a moderate pericardial effusion along with gadolinium uptake consistent with perimyocarditis. Cabozanitib was discontinued and Colchicine 0.6 mg daily started. Eventually, LVEF normalized and pericardial effusion resolved. Patient was restarted on Cabozanitib 20mg and has remained stable from a cardiovascular standpoint Discussion: In the past decade the rise of tyrosine kinase inhibitors, like Cabozantinib, have transformed the scope of medical oncology. In 2019 Al hussein et al described the first case of Cabozantinib induced cardiomyopathy. We present, to our knowledge, the second reported case. This case identifies a strong temporal relationship between Cabozantinib, LV systolic dysfunction and perimyocarditis with higher doses. Interestingly, our patient received Pembrolizumab for 2 years, but had heart failure symptoms only 1 month after Cabozanitib initiation. Although theoretically possible, it is unlikely Pembrolizumab was the cause, given normal TTE 2 years after initiation and strong temporal relationship to Cabozantinib. Further studies are required to establish the cardiotoxic side effects of Cabozantinib and inform guidance on cardiac monitoring.
133P Novel fully human agonist antibodies against the T-cell costimulatory receptor CD27 shape adaptive anti-tumor immunity
Authors: T. Guillaudeux, Y. Ovechkina, S. Sridhar, D. Peckham, J. Cross, N. Eyde, E. Frazier, N. Kabi, R. Lance, M. Xu, E. Tarcha, S. Iadonato
Journal: Annals of Oncology (2021)
Reading Frame Repair of <i>TTN</i> Truncation Variants Restores Titin Quantity and Functions
Authors: Robert Romano, Shahnaz Ghahremani, Talia Zimmerman, Nicholas Legere, Ketan Thakar, Feria A. Ladha, Anthony M. Pettinato, J. Travis Hinson
Journal: Circulation (2021)

Titin truncation variants (TTNtvs) are the most common inheritable risk factor for dilated cardiomyopathy (DCM), a disease with high morbidity and mortality. The pathogenicity of TTNtvs has been associated with structural localization as A-band variants overlapping myosin heavy chain-binding domains are more pathogenic than I-band variants by incompletely understood mechanisms. Demonstrating why A-band variants are highly pathogenic for DCM could reveal new insights into DCM pathogenesis, titin (TTN) functions, and therapeutic targets.
Inclusion of Smoking Data in Cardiovascular Disease Risk Estimation
Authors: Meredith S. Duncan, Robert A. Greevy, Hilary A. Tindle, Ramachandran S. Vasan, Loren Lipworth, Melinda C. Aldrich, Donald M. Lloyd-Jones, Matthew S. Freiberg
Journal: JAMA Cardiology (2021)

<h3>Importance</h3> Former heavy smokers (ie, those with ≥20 pack-years of smoking) may have higher atherosclerotic cardiovascular disease (ASCVD) risk than never smokers for up to 16 years after smoking cessation. However, the 2013 pooled cohort equations (PCE) do not account for pack-years of smoking and only consider current vs noncurrent smoking status without distinguishing former smokers from never smokers. <h3>Objective</h3> To assess the predictive utility of smoking history when added to the PCE using data from 18 400 person examinations among Framingham offspring participants. <h3>Design, Setting, and Participants</h3> This is a retrospective analysis of prospectively collected data from the Framingham Heart Study, a community-based cohort. Framingham Heart Study offspring cohort participants attending their first examination (1971-1975) who were followed-up through December 2016 were included. <h3>Exposures</h3> Self-reported current/former/never smoking status, pack-years smoked, and years since quitting. <h3>Main Outcomes and Measures</h3> Incident ASCVD (myocardial infarction, fatal/nonfatal ischemic stroke, coronary heart disease death). <h3>Results</h3> Of 3908 patients, there were 358 and 197 events among 1895 men and 2013 women, respectively, with a mean (SD) age of 55 (9.5) years. Ever smoking prevalence was high (6474 men [77%] and 7760 women [78%]), as were median pack-years (men: 39; women: 32 overall person examinations). Four sex-specific ASCVD risk prediction models were built using pooled-repeated Cox proportional hazards regression. The PCEs were was fit in this sample with continuous predictors on their natural scale (ie, not logarithmically transformed) as well as polynomials accounting for nonlinearity and then cumulatively adjusted for former smoking, pack-years, and years since quitting. Models were compared via change in C statistic, continuous net reclassification improvement (NRI[&gt;0]), and relative integrated discrimination improvement (rIDI). Including former smoking status, pack-years, and years since quitting had significant but modest NRI(&gt;0) and rIDI values compared with the PCE with continuous variables on their natural scale in both sexes (men: NRI[&gt;0] = 0.23; rIDI = 0.19; women: NRI[&gt;0] = 0.34, rIDI = 0.11; change in C statistic = 0.01 for both). <h3>Conclusions and Relevance</h3> Former smoking, pack-years, and years since quitting significantly improved ASCVD risk prediction in this sample. The Framingham Heart Study offspring cohort is largely composed of non-Hispanic White participants of European ancestry. If results are validated in cohorts of race and ethnicity groups other than White, these variables could be considered for inclusion in future ASCVD risk prediction models.
A glomerular transcriptomic landscape of apolipoprotein L1 in Black patients with focal segmental glomerulosclerosis
Authors: Michelle T. McNulty, Damian Fermin, Felix Eichinger, Dongkeun Jang, Matthias Kretzler, Noël P. Burtt, Martin R. Pollak, Jason Flannick, Astrid Weins, David J. Friedman, Matthew G. Sampson, K. Dell, J. Sedor, M. Schachere, J. Negrey, K. Lemley, B. Silesky, T. Srivastava, A. Garrett, C. Sethna, K. Laurent, P. Canetta, A. Pradhan, L. Greenbaum, C. Wang, C. Kang, S. Adler, J. LaPage, A. Athavale, M. Itteera, M. Atkinson, T. Dell, F. Fervenza, M. Hogan, J. Lieske, V. Chernitskiy, F. Kaskel, M. Ross, P. Flynn, J. Kopp, J. Blake, H. Trachtman, O. Zhdanova, F. Modersitzki, S. Vento, R. Lafayette, K. Mehta, C. Gadegbeku, S. Quinn-Boyle, M. Hladunewich, H. Reich, P. Ling, M. Romano, A. Fornoni, C. Bidot, M. Kretzler, D. Gipson, A. Williams, C. Klida, V. Derebail, K. Gibson, E. Cole, J. Ormond-Foster, L. Holzman, K. Meyers, K. Kallem, A. Swenson, K. Sambandam, Z. Wang, M. Rogers, A. Jefferson, S. Hingorani, K. Tuttle, M. Bray, E. Pao, A. Cooper, J.J. Lin, Stefanie Baker, M. Kretzler, L. Barisoni, J. Bixler, H. Desmond, S. Eddy, D. Fermin, C. Gadegbeku, B. Gillespie, D. Gipson, L. Holzman, V. Kurtz, M. Larkina, S. Li, S. Li, C.C. Lienczewski, J. Liu, T. Mainieri, L. Mariani, M. Sampson, J. Sedor, A. Smith, A. Williams, J. Zee, Carmen Avila-Casado, Serena Bagnasco, Joseph Gaut, Stephen Hewitt, Jeff Hodgin, Kevin Lemley, Laura Mariani, Matthew Palmer, Avi Rosenberg, Virginie Royal, David Thomas, Jarcy Zee, Laura Barisoni, Cynthia Nast, K. Dell, J. Sedor, M. Schachere, J. Negrey, K. Lemley, B. Silesky, T. Srivastava, A. Garrett, C. Sethna, K. Laurent, P. Canetta, A. Pradhan, L. Greenbaum, C. Wang, C. Kang, S. Adler, J. LaPage, A. Athavale, M. Itteera, M. Atkinson, T. Dell, F. Fervenza, M. Hogan, J. Lieske, V. Chernitskiy, F. Kaskel, M. Ross, P. Flynn, J. Kopp, J. Blake, H. Trachtman, O. Zhdanova, F. Modersitzki, S. Vento, R. Lafayette, K. Mehta, C. Gadegbeku, S. Quinn-Boyle, M. Hladunewich, H. Reich, P. Ling, M. Romano, A. Fornoni, C. Bidot, M. Kretzler, D. Gipson, A. Williams, C. Klida, V. Derebail, K. Gibson, E. Cole, J. Ormond-Foster, L. Holzman, K. Meyers, K. Kallem, A. Swenson, K. Sambandam, Z. Wang, M. Rogers, A. Jefferson, S. Hingorani, K. Tuttle, M. Bray, E. Pao, A. Cooper, J.J. Lin, Stefanie Baker, M. Kretzler, L. Barisoni, J. Bixler, H. Desmond, S. Eddy, D. Fermin, C. Gadegbeku, B. Gillespie, D. Gipson, L. Holzman, V. Kurtz, M. Larkina, S. Li, S. Li, C.C. Lienczewski, J. Liu, T. Mainieri, L. Mariani, M. Sampson, J. Sedor, A. Smith, A. Williams, J. Zee, Carmen Avila-Casado, Serena Bagnasco, Joseph Gaut, Stephen Hewitt, Jeff Hodgin, Kevin Lemley, Laura Mariani, Matthew Palmer, Avi Rosenberg, Virginie Royal, David Thomas, Jarcy Zee, Laura Barisoni, Cynthia Nast
Journal: Kidney International (2021)
No more band-aids: health-care system reform
Authors: None The Lancet Healthy Longevity
Journal: The Lancet Healthy Longevity (2021)

The COVID-19 pandemic has seen health-care systems around the world crippled by overburdening, which is now compounded by a mass exodus of personnel due to vaccination refusal. Many countries have mandated vaccination for health-care workers, with those refusing left without a job. After this mandate went into effect in France in September, 2021, 3000 health-care workers were suspended for not complying. Although this affects all health-care sectors, this sudden dearth of employees has taken a particular toll on the care of older adults—an already underfunded sector plagued by high staff turnover and access barriers for patients.
Abstract 11617: Personalizing Outcomes After Child Cardiac Arrest (POCCA): A Preliminary Biomarker Report
Authors: Ericka L Fink, Patrick M Kochanek, Ashok Panigrahy, Sue R Beers, Rachel P Berger, HULYA BAYIR, Chunyan Wang, Jose Pineda, Alexis A Topjian, aline maddux, Frederick Willyerd, Elizabeth A Hunt, Melissa G Chung, Christopher Newth, Lincoln Smith, Leslie Doughty, J Wesley Diddle, Juan Piantino, Karen H Walson, Binod Balakrishnan, Stuart Friess, Ashley Siems, Robert M Clark, Anthony Fabio
Journal: Circulation (2021)

Blood-based brain injury biomarkers show promise to prognosticate outcome for children resuscitated from cardiac arrest. The objective of this multicenter, observational study was to validate promising biomarkers to accurately prognosticate outcome at 1 year. Early brain injury biomarkers will be associated with outcome at one year for children with cardiac arrest. Fourteen centers in the US enrolled children aged &lt; 18 years with in- or out-of-hospital cardiac arrest and pediatric intensive care unit admission if pre-cardiac arrest Pediatric Cerebral Performance Category score was 1-3. Glial fibrillary acidic protein (GFAP), ubiquitin carboxyl-terminal esterase L1 (UCHL1), neurofilament light (NfL), and Tau protein concentrations were measured in samples drawn post-arrest day 1 using Quanterix Simoa 4-Plex assay. The primary outcome was unfavorable outcome at one year (Vineland Adaptive Behavioral Scale &lt; 70). Of 164 children enrolled, 120 children had evaluable data (n=50 with unfavorable outcome). Children were median (interquartile range) 1 (0-8.5) years of age, 41% female, and 60% had asphyxia etiology. Of children with unfavorable outcome, 93% had unwitnessed arrests and 43 died. While all 4 day 1 biomarkers were increased in children with unfavorable vs. favorable outcome at 1-year post-arrest, NfL had the best univariate area under the receiver operator curve to predict 1 year outcome at 0.731. In a multivariate logistic regression, NfL concentration trended toward significance on day 1 and was associated with unfavorable outcome at 1-year on days 2 and 3 (day 1: Odds Ratio [95% Confidence Interval] 1.004 [1.000-1.008], p=.062; day 2: 1.005 [1.002-1.008], p=.003, and day 3: 1.002 [1.001-1.004], p=.003, respectively). UCHL1 was associated with outcome on days 2: 1.005 [1.002-1.009], p=.003 and 3: 1.001 [1.000-1.002], p=.019) and Tau trended toward association with outcome on days 2: 1.003 [1.000-1.005], p=.08) and 3: 1.001 [1.000-1.002], p=.077. Brain injury biomarkers predict unfavorable outcome post-pediatric cardiac arrest. Accuracy of biomarkers alone and together with other prognostication tools should be evaluated to predict long term child centered outcomes post-cardiac arrest.
Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis
Authors: Jacob E. Berchuck, Sylvan C. Baca, Heather M. McClure, Keegan Korthauer, Harrison K. Tsai, Pier Vitale Nuzzo, Kaitlin M. Kelleher, Monica He, John A. Steinharter, Soumya Zacharia, Sandor Spisak, Ji-Heui Seo, Vincenza Conteduca, Olivier Elemento, Joonghoon Auh, Michael Sigouros, Eva Corey, Michelle S. Hirsch, Mary-Ellen Taplin, Toni K. Choueiri, Mark M. Pomerantz, Himisha Beltran, Matthew L. Freedman
Journal: Clinical Cancer Research (2021)

Neuroendocrine prostate cancer (NEPC) is a resistance phenotype that emerges in men with metastatic castration-resistant prostate adenocarcinoma (CR-PRAD) and has important clinical implications, but is challenging to detect in practice. Herein, we report a novel tissue-informed epigenetic approach to noninvasively detect NEPC.
Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival
Authors: Manish A Shah, David Cunningham, Jean-Philippe Metges, Eric Van Cutsem, Zev Wainberg, Emon Elboudwarej, Kai-Wen Lin, Scott Turner, Marianna Zavodovskaya, David Inzunza, Jinfeng Liu, Scott D Patterson, Jingzhu Zhou, Jing He, Dung Thai, Pankaj Bhargava, Carrie Baker Brachmann, Daniel V T Cantenacci
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background Matrix metalloproteinase-9 (MMP9) selectively cleaves extracellular matrix proteins contributing to tumor growth and an immunosuppressive microenvironment. This study evaluated andecaliximab (ADX), an inhibitor of MMP9, in combination with nivolumab (NIVO), for the treatment of advanced gastric cancer. Methods Phase 2, open-label, randomized multicenter study evaluating the efficacy, safety, and pharmacodynamics of ADX+NIVO versus NIVO in patients with pretreated metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. The primary endpoint was objective response rate (ORR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), and adverse events (AEs). We explored the correlation of efficacy outcomes with biomarkers. Results 144 patients were randomized; 141 were treated: 81% white, 69% male, median age was 61 years in the ADX+NIVO group and 62 years in the NIVO-alone group. The ORR was 10% (95% CI 4 to 19) in the ADX+NIVO group and 7% (95% CI 2 to 16) in the NIVO-alone group (OR: 1.5 (95% CI 0.4 to 6.1; p=0.8)). There was no response or survival benefit associated with adding ADX. AE rates were comparable in both treatment groups; the most common AEs were fatigue, decreased appetite, nausea, and vomiting. Programmed cell death ligand 1, interferon-γ (IFN), and intratumoral CD8+ cell density were not associated with treatment response or survival. The gene signature most correlated with shorter survival was the epithelial-to-mesenchymal gene signature; high transforming growth factor (TGF)-β fibrosis score was negatively associated with OS (p=0.036). Gene expression analysis of baseline tumors comparing long-(1+ years) and short-term (&lt;1 year) survivors showed that GRB7 was associated with survival beyond 1 year. Human epidermal growth factor receptor 2 (HER2)-positive disease was associated with significantly longer survival (p=0.0077). Median tumor mutation burden (TMB) was 2.01; patients with TMB ≥median had longer survival (p=0.0025) and improved PFS (p=0.016). Based on a model accounting for TMB, TGF-β fibrosis, and HER2, TMB was the main driver of survival in this patient population. Conclusion Combination of ADX+NIVO had a favorable safety profile but did not improve efficacy compared with NIVO alone in patients with pretreated metastatic gastric or GEJ adenocarcinoma. HER2 positivity, higher TMB or GRB7, and lower TGF-β were associated with improved outcomes. Trial registration number NCT02864381 or GS-US-296–-2013.
Biased Outcome reporting Guidelines for Underwhelming Studies (BOGUS) statement and checklist
Authors: Greta R Bauer
Journal: BMJ (2021)

The uptake and destruction of bacteria by phagocytic cells is an essential defense mechanism in metazoans. To identify novel genes involved in the phagocytosis of <i>Staphylococcus aureus</i>, a major human pathogen, we assessed the phagocytic capacity of adult blood cells (hemocytes) of the fruit fly, <i>Drosophila melanogaster,</i> by testing several lines of the Drosophila Genetic Reference Panel. Natural genetic variation in the gene <i>RNA-binding Fox protein 1</i> (<i>Rbfox1</i>) correlated with low phagocytic capacity in hemocytes, pointing to Rbfox1 as a candidate regulator of phagocytosis. Loss of Rbfox1 resulted in increased expression of the Ig superfamily member <i>Down syndrome adhesion molecule 4</i> (<i>Dscam4</i>). Silencing of <i>Dscam4</i> in Rbfox1-depleted blood cells rescued the fly’s cellular immune response to <i>S. aureus</i>, indicating that downregulation of <i>Dscam4</i> by Rbfox1 is critical for <i>S. aureus</i> phagocytosis in <i>Drosophila</i>. To our knowledge, this study is the first to demonstrate a link between <i>Rbfox1, Dscam4,</i> and host defense against <i>S. aureus</i>.
Is COVID-19 the Newest Comorbidity of Obesity Mitigated by Bariatric Surgery?
Authors: Paulina Salminen, Gerhard Prager, Phil R. Schauer
Journal: JAMA Surgery (2021)

Ali Aminian, MD; Chao Tu, MS; Alex Milinovich, BA; Kathy E. Wolski, MPH; Michael W. Kattan, PhD; Steven E. Nissen, MD